New Changes in the Summary Meeting of Pharmaceutical Sales Companies
Release time:
2020-08-14
New Changes in the Summary Meeting of Pharmaceutical Sales Company
News from our newspaper 7# July 19 , Pharmaceutical Sales Company held a work meeting for the first half of the year, and the reporter found that there were some new changes in the meeting.
One of the changes, the regional manager PPT reports and motivates. As a peak salesperson, it is the window to the outside of the peak. Its expression ability and manners all represent the image of the peak. For this reason, the pharmaceutical sales company specially requires each office manager of agency sales and terminal sales to report the work in the first half of the year in the form of PPT . The report includes product sales, new customer development, existing problems, next work, suggestions to the company, etc. The management and logistics service personnel of the sales company serve as scoring personnel, according to the overall reporting effect, language expression ability, etiquette image, work priorities in the first half of the year and work plan in the second half of the year, each reporter is scored, and the ranking is automatically counted through the system platform, and certain rewards are given to the top ranking. Zhou Wenyi, general manager of the pharmaceutical sales company, said that the main purpose of implementing this incentive measure is to hope that regional managers can express the problems in their respective regional markets and follow-up work in the form of words through the production and report of PPT , so as to further clarify the working ideas and better plan the work in the second half of the year. The sales company's semi-annual meeting and year-end meeting will also continue to adopt the PPT reporting form, and will increase incentives to a certain extent.
The second change is to solve the problems raised by the sales area on the spot. Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, based on the questions and suggestions raised by the regional managers in the report, put forward thinking questions from the aspects of consistency evaluation progress, packaging quality, product out of stock, drug quality, drug fleeing, control of drug proportion, and compliance of sales expenses. In the discussion session of this meeting, members of the management team and business personnel of the pharmaceutical company discussed and answered the crux of the existing problems and solutions.
change three, strengthen the production and marketing docking. During the meeting, the pharmaceutical sales company organized sales staff to visit the production line, packaging workshop, product warehouse, etc. of the comprehensive preparation workshop of Jinxi Pharmaceutical Factory, and learned about the production process, process, facilities and equipment, quality control and product inventory of the drugs on the spot, so that the sales staff can better introduce the products in the process of communicating with customers.
Zhou Wenyi said that through the adjustment of meeting forms, assessment incentives, work measures, etc., salesmen can fully feel the challenges brought by changes in the pharmaceutical industry to their jobs and stimulate employees' work initiative. At the same time, the sales company will continue to improve to improve the overall quality of business personnel, enhance the cohesion and centripetal force of employees, and keep up with the development of the pharmaceutical industry. (Xu Yuting, Ni Yingzhen, Wang Hongfeng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page